Induction of Immunoglobulin Transcription Factor 2 and Resistance to MEK Inhibitor in Melanoma Cells
Overview
Authors
Affiliations
Primary or acquired resistance to MEK inhibitors has been a barrier to successful treatment with MEK inhibitors in many tumors. In this study, we analyzed genome-wide gene expression profiling data from 6 sensitive and 6 resistant cell lines to identify candidate genes whose expression changes are associated with responses to a MEK inhibitor, selumetinib (AZD6244). Of 62 identified differentially expressed genes, we selected Immunoglobulin Transcription Factor 2, also known as transcription factor 4 as a potential drug resistance marker for further analysis. This was because the ITF-2 expression increase in resistant cell lines was relatively high and a previous study has suggested that ITF-2 functions as an oncogene in human colon cancers. We also established an AZD6244 resistant cell line (M14/AZD-3) from an AZD6244 sensitive M14 cell line. The expression of the ITF-2 was elevated both in primary AZD6244 resistant cell line, LOX-IMVI and acquired resistant cell line, M14/AZD-3. Targeted silencing of ITF-2 by siRNA significantly enhanced susceptibility to AZD6244 in resistant cells. Wnt/β-catenin pathway was activated through direct interaction of p-ERK and GSK3β. Our results suggest that up-regulation of the ITF-2 gene expression is associated with cellular resistance to MEK inhibitors, and activation of Wnt signaling pathway through interaction of p-ERK and GSK3β seems to be a mechanism for increase of ITF-2.
Loras A, Gil-Barrachina M, Marques-Torrejon M, Perez-Pastor G, Martinez-Cadenas C Life (Basel). 2022; 12(9).
PMID: 36143375 PMC: 9503451. DOI: 10.3390/life12091339.
Fang X, Kim Y, Lee Y, Lee M, Lim W, Yim W Nutrients. 2022; 14(7).
PMID: 35406121 PMC: 9002362. DOI: 10.3390/nu14071508.
Resistance to Molecularly Targeted Therapies in Melanoma.
Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K Cancers (Basel). 2021; 13(5).
PMID: 33807778 PMC: 7961479. DOI: 10.3390/cancers13051115.
Chen Y, Jiang P, Wen J, Wu Z, Li J, Chen Y Cancer Med. 2020; 9(8):2918-2929.
PMID: 32096603 PMC: 7163086. DOI: 10.1002/cam4.2934.
Role of miR-214 in regulation of β-catenin and the malignant phenotype of melanoma.
Prabhakar K, Rodriguez C, Jayanthy A, Mikheil D, Bhasker A, Perera R Mol Carcinog. 2019; 58(11):1974-1984.
PMID: 31338875 PMC: 6800786. DOI: 10.1002/mc.23089.